BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 15586384)

  • 41. A novel role for the mineralocorticoid receptor in glucocorticoid driven vascular calcification.
    Zhu D; Rashdan NA; Chapman KE; Hadoke PW; MacRae VE
    Vascul Pharmacol; 2016 Nov; 86():87-93. PubMed ID: 27153999
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Benzofuran derivatives inhibit 11β-hydroxysteroid dehydrogenase type 1 activity in rat adipose tissue.
    Kiyonaga D; Tagawa N; Yamaguchi Y; Wakabayashi M; Kogure T; Ueda M; Miyata O; Kobayashi Y
    Biol Pharm Bull; 2012; 35(8):1275-80. PubMed ID: 22863925
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 4-(Phenylsulfonamidomethyl)benzamides as potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1 with efficacy in diabetic ob/ob mice.
    Zhang X; Zhou Z; Yang H; Chen J; Feng Y; Du L; Leng Y; Shen J
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4455-8. PubMed ID: 19564108
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone (KR-66344).
    Park JS; Rhee SD; Kang NS; Jung WH; Kim HY; Kim JH; Kang SK; Cheon HG; Ahn JH; Kim KY
    Biochem Pharmacol; 2011 Apr; 81(8):1028-35. PubMed ID: 21315688
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Carbon monoxide stimulates insulin release and propagates Ca2+ signals between pancreatic beta-cells.
    Lundquist I; Alm P; Salehi A; Henningsson R; Grapengiesser E; Hellman B
    Am J Physiol Endocrinol Metab; 2003 Nov; 285(5):E1055-63. PubMed ID: 14534076
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models.
    Okazaki S; Takahashi T; Iwamura T; Nakaki J; Sekiya Y; Yagi M; Kumagai H; Sato M; Sakami S; Nitta A; Kawai K; Kainoh M
    J Pharmacol Exp Ther; 2014 Oct; 351(1):181-9. PubMed ID: 25100752
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacological evaluation of adipose dysfunction via 11β-hydroxysteroid dehydrogenase type 1 in the development of diabetes in diet-induced obese mice with cortisone pellet implantation.
    Akiyama N; Akiyama Y; Kato H; Kuroda T; Ono T; Imagawa K; Asakura K; Shinosaki T; Murayama T; Hanasaki K
    J Pharmacol Exp Ther; 2014 Apr; 349(1):66-74. PubMed ID: 24511146
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11beta-hydroxysteroid dehydrogenase type 1) gene.
    Iwasaki Y; Takayasu S; Nishiyama M; Tsugita M; Taguchi T; Asai M; Yoshida M; Kambayashi M; Hashimoto K
    Mol Cell Endocrinol; 2008 Mar; 285(1-2):10-8. PubMed ID: 18313835
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 11β-Hydroxysteroid Dehydrogenase Type 1 in Obese Subjects With Type 2 Diabetes Mellitus.
    Li X; Wang J; Yang Q; Shao S
    Am J Med Sci; 2017 Oct; 354(4):408-414. PubMed ID: 29078846
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antisense reduction of 11β-hydroxysteroid dehydrogenase type 1 enhances energy expenditure and insulin sensitivity independent of food intake in C57BL/6J mice on a Western-type diet.
    Li G; Hernandez-Ono A; Crooke RM; Graham MJ; Ginsberg HN
    Metabolism; 2012 Jun; 61(6):823-35. PubMed ID: 22209663
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Contribution of endogenous glucocorticoids and their intravascular metabolism by 11β-HSDs to postangioplasty neointimal proliferation in mice.
    Iqbal J; Macdonald LJ; Low L; Seckl JR; Yau CW; Walker BR; Hadoke PW
    Endocrinology; 2012 Dec; 153(12):5896-905. PubMed ID: 23125311
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genistein inhibits glucocorticoid amplification in adipose tissue by suppression of 11β-hydroxysteroid dehydrogenase type 1.
    Tagawa N; Kubota S; Kobayashi Y; Kato I
    Steroids; 2015 Jan; 93():77-86. PubMed ID: 25447798
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 11beta-Hydroxysteroid dehydrogenase 1 reductase activity is dependent on a high ratio of NADPH/NADP(+) and is stimulated by extracellular glucose.
    Dzyakanchuk AA; Balázs Z; Nashev LG; Amrein KE; Odermatt A
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):137-41. PubMed ID: 18778749
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Regulation of glucocorticoid sensitivity in thymocytes from burn-injured mice.
    D'Elia M; Patenaude J; Bernier J
    Am J Physiol Endocrinol Metab; 2009 Jan; 296(1):E97-104. PubMed ID: 19001548
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors still improve metabolic phenotype in male 11β-HSD1 knockout mice suggesting off-target mechanisms.
    Harno E; Cottrell EC; Yu A; DeSchoolmeester J; Gutierrez PM; Denn M; Swales JG; Goldberg FW; Bohlooly-Y M; Andersén H; Wild MJ; Turnbull AV; Leighton B; White A
    Endocrinology; 2013 Dec; 154(12):4580-93. PubMed ID: 24169553
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains.
    Alberts P; Nilsson C; Selen G; Engblom LO; Edling NH; Norling S; Klingström G; Larsson C; Forsgren M; Ashkzari M; Nilsson CE; Fiedler M; Bergqvist E; Ohman B; Björkstrand E; Abrahmsen LB
    Endocrinology; 2003 Nov; 144(11):4755-62. PubMed ID: 12960099
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Expression of 11β-hydroxysteroid dehydrogenase 1 and 2 in patients with chronic rhinosinusitis and their possible contribution to local glucocorticoid activation in sinus mucosa.
    Jun YJ; Park SJ; Kim TH; Lee SH; Lee KJ; Hwang SM; Lee SH
    J Allergy Clin Immunol; 2014 Oct; 134(4):926-934.e6. PubMed ID: 24810847
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects.
    Alberti L; Girola A; Gilardini L; Conti A; Cattaldo S; Micheletto G; Invitti C
    Int J Obes (Lond); 2007 Dec; 31(12):1826-31. PubMed ID: 17593901
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enhancement of glucocorticoid-induced 11beta-hydroxysteroid dehydrogenase type 1 expression by proinflammatory cytokines in cultured human amnion fibroblasts.
    Sun K; Myatt L
    Endocrinology; 2003 Dec; 144(12):5568-77. PubMed ID: 12960005
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Resveratrol inhibits 11β-hydroxysteroid dehydrogenase type 1 activity in rat adipose microsomes.
    Tagawa N; Kubota S; Kato I; Kobayashi Y
    J Endocrinol; 2013 Sep; 218(3):311-20. PubMed ID: 23814014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.